共 99 条
- [21] Ishak KG(2005)Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C Nephrol Dial Transplant 20 991-580
- [22] Black WC(2006)Pegylated (40ku) Interferon alpha 2a (Pegasys) is unaffected by renal impairment (Abstract) J Gastroenterol Hepatol 21 575-297
- [23] Mousa DH(2000)Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis Hepatology 32 842-4194
- [24] Abdalla AH(2005)Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis treatment Saudi J Kidney Dis Transplant. 16 293-44
- [25] Al-Shoail G(2006)Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers.Aliment. Pharmacol J Gastroenterol 14 4191-230
- [26] Ayoola EA(2004)American Gastroenterological Association medical position statement on the management of hepatitis C Ther 20 37-801
- [27] Huraib S(2006)Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit Gastroenterology 130 225-321
- [28] Arif M(2006)Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients J Nephrol 19 794-774
- [29] Hussein MM(2006)The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kD) plus ribavirin in haemodialysed patients awaiting renal transplant J Viral Hepat 13 316-292
- [30] Mooij JM(2007)Ribavirin treatment in dialysis patients with chronic hepatitis C infection: a pilot study J Hepatol 46 768-443